EU Ban to Cost India Pharmaceutical Exports Worth $1Billion

2015-07-28-pharmHYDERABAD, India—India could lose about $1-1.2 billion worth of pharmaceutical exports due to the decision taken by the European Commission to ban 700 generic drugs for alleged manipulation of clinical trials by the Hyderabad-based contract research organization GVK Biosciences Pvt. Ltd, said a top executive of the Pharmaceutical Export Promotion Council (Pharmexcil).
The European Commission is the executive body of the European Union (EU) responsible for proposing legislation and implementing decisions.
“We estimate the impact of the European Union ban to be around $1 billion to $ 1.2 billion,” said P.V. Appaji, director general of Pharmaexcil, an agency under the Union Ministry of Commerce and Industry, on the sidelines of an industry event in Hyderabad.
India exported $15.4 billion or Rs.94,275 crore worth of pharmaceutical products in 2014-15, with Europe accounting for 20% or $3 billion.
He also said, out of $3 billion, formulations or generic drug exports constituted about $1billion and active pharmaceutical ingredients formed $2 billion.
Appaji said the commerce ministry is expected to discuss the implications of this decision and the steps that need to be taken in meetings over the next two days.


  1. An excellent move by the EU. This was inevitable as India has no safety measures for pharma products and foods. Other Western countries will no doubt follow soon. All countries should ban Indian pharma products and foods.

    Indian exported food such as Maggi Noodles, Haldiram products and MANY OTHERS are dangerous to health and have been shown to cause cancer. In fact, Maggi Noodles and others were even banned in India.


Please enter your comment!
Please enter your name here